Patents by Inventor Xiaoyue Zhang

Xiaoyue Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GALUNISERTIB CRYSTALLINE FORM, PREPARATION METHOD THEREOF AND USE THEREOF
    Publication number: 20190241572
    Abstract: The present disclosure relates to a novel crystalline form of Galunisertib, processes for preparation and use thereof. The present disclosure also relates to a pharmaceutical composition comprises the novel crystalline form of Galunisertib and use of the novel crystalline form of Galunisertib and pharmaceutical composition for preparing drugs treating disease. The crystalline form of the present disclosure has good stability, solubility and hygroscopicity, which has significant value for future drug optimization and development.
    Type: Application
    Filed: July 21, 2017
    Publication date: August 8, 2019
    Applicants: Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmaceutical (Suzhou) Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Yuhao Chen, Hui Gao, Fei Lu, Xiaoyu Zhang
  • Method of automatically modifying imaging range in biological sample microscopic imaging
    Patent number: 10365207
    Abstract: A method for automatically altering an imaging area in microscopic imaging of a biological sample. In the method, a sample outline is differentiated from surrounding tissues by means of endogenous or exogenous markers; an initial sample imaging area is set; optical microscopic imaging is performed on a sample surface layer, wherein the imaging area is larger than an area to be imaged of the sample; an actual sample area is calculated by an outline identification algorithm using an imaging result of the sample surface layer and is set as an imaging area of next layer; optical microscopic imaging is performed on a sample to be imaged of the next layer according to the set imaging area, wherein the imaging area covers the area to be imaged of the sample and no redundant imaging is performed; and the above steps are repeated until a data acquisition task is completed.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: July 30, 2019
    Assignee: WUHAN OE-BIO CO., LTD.
    Inventors: Hui Gong, Jing Yuan, Xiaoyu Zhang, Qiuyuan Zhong
  • Surgical knife safety handle having user operable lock
    Patent number: 10357279
    Abstract: A surgical knife safety device having a handle, a blade connected to the handle, and a guard carried by the handle for sliding movement between a retracted position in which the blade is exposed for use, and an extended position for covering the sharp cutting edge of the blade. In the retracted position, an enlarged guard radius is provided at the distal end of the handle to allow improved handle control and blade orientation. The enlarged guard radius is positioned to allow the user to firmly grip a large distal handle portion which is preferably molded as a single piece with the blade holder, preventing unwanted blade or handle movement due to guard mechanism tolerances. A spring, such as leaf spring or a cantilever beam, and a pair of detents or slots are provided to fix the guard in the extended or retracted position and to provide resistance during movement between the two positions.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: July 23, 2019
    Assignee: Beaver-Visitec International (US), Inc.
    Inventors: Dana Cote, Brian Rapp, Paul Karnafel, Xiaoyu Zhang
  • Novel Crystalline Form of Lenvantinib Mesylate and Process of Preparation Thereof
    Publication number: 20190218184
    Abstract: The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer. The novel crystalline form of mesylate of the present disclosure has good solubility, stability, and remarkable purification effect in process. The preparation method of this novel crystalline form is simple, low cost, and has an important value for future optimization and development of the drug.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 18, 2019
    Applicant: CRYSTAL PHARMATECH CO., LTD
    Inventors: Minhua CHEN, Yanfeng ZHANG, Xiaojuan DIAO, Xiaoyu ZHANG
  • CRYSTAL FORMS OF NBI-98854, PREPARATION METHOD AND USE THEREOF
    Publication number: 20190218209
    Abstract: The present disclosure relates to novel crystalline forms of NBI-98854 (as shown in formula I), preparation process and use thereof. The crystalline forms of NBI-98854 provided by the present disclosure, named as Form CS1 and Form CS2, can be used for preparing drug product treating tardive dyskinesia. The crystalline forms of NBI-98854 provided by the present disclosure have pharmaceutically acceptable solubility and hygroscopicity, good stability and are stable during storage, thereby avoiding changes in drug solubility, dissolution rate, bioavailability and efficacy due to polymorph transformation. This provides a new and better choice for the preparation of drug product containing NBI-98854, which has significant value for future drug development.
    Type: Application
    Filed: June 29, 2017
    Publication date: July 18, 2019
    Inventors: Minhua Chen, Yanfeng Zhang, Po Zou, Kai Liu, Jinqiu Wang, Xiaoyu Zhang
  • Crystalline forms of lesinurad and its sodium salt
    Patent number: 10351536
    Abstract: Novel crystalline forms of lesinurad and its sodium salt, processes for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transporter 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: July 16, 2019
    Assignees: Crystal Pharmatech Co., Ltd., Suzhou Pengxu Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Xiaoyu Zhang, Peng Wang, Pixu Li
  • Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof
    Patent number: 10323035
    Abstract: The present disclosure relates to novel co-crystals of a CDK inhibitor and an MEK inhibitor and the preparation methods thereof. Specifically, the present disclosure provides hydrates or anhydrates which are named as Form I, Form II and Form III. The novel co-crystals provided in the present disclosure have good stability, low hygroscopicity and high solubility, and have an important value for further optimization and development of the drug.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: June 18, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Qiyue Liu, Nan Xia, Chaohui Yang, Xiaoyu Zhang
  • CRYSTALLINE FORMS OF JAK1-SELECTIVE INHIBITOR, PROCESSES FOR PREPARATION AND USE THEREOF
    Publication number: 20190177314
    Abstract: The present disclosure relates to crystalline forms of JAK1-selective inhibitor, process for preparation and use for prevention and/or treatment of diseases associated with JAK family. The crystalline forms of the present disclosure show favorable properties such as simple preparation process, good stability, low hygroscopicity and good mechanical stability.
    Type: Application
    Filed: August 3, 2017
    Publication date: June 13, 2019
    Inventors: Minhua Chen, Yanfeng Zhang, Cunbo Yang, Kai Liu, Xiaoyu Zhang
  • NEW CRYSTAL FORM OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR PROCESSES FOR PREPARATION AND USE THEREOF
    Publication number: 20190169219
    Abstract: The present disclosure relates to novel crystalline forms of a sodium-glucose co-transporter inhibitor drug (Sotagliflozin), processes for preparation and use thereof. The present disclosure also relates to pharmaceutical composition comprises novel crystalline forms of Sotagliflozin and use of novel crystalline forms and pharmaceutical composition of Sotagliflozin for preparing drugs for treating diseases. The crystalline forms provided by the present disclosure have advantages of good stability, relatively low hygroscopicity, suitability for process development and post-treatment, simple processes for preparation, low cost, and has significant value for future drug optimization and development.
    Type: Application
    Filed: May 25, 2017
    Publication date: June 6, 2019
    Applicant: CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.
    Inventors: Minhua CHEN, Yanfeng ZHANG, Po ZOU, Kai LIU, Xiaoyu ZHANG
  • Crystal form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxole-5-yl)cyclopropane formamido)-3-methylpyridine-2-yl)benzoic acid and preparation method thereof
    Patent number: 10308641
    Abstract: The present disclosure provides crystalline form A of 3-(6-(1-(2, 2-difluorobenzo [d] [1, 3] dioxo-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and process of preparation thereof. The crystalline form A has low hygroscopicity, good stability, is convenient to store. It has higher solubility than that of prior art and therefore plays an important role in further optimization and development of the drug.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: June 4, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Kai Liu, Po Zou, Xiaoyu Zhang
  • Crystalline form A of obeticholic acid and preparation method thereof
    Patent number: 10273262
    Abstract: The present invention relates to crystalline Form A of obeticholic acid and the preparation method thereof. The present invention provides Form A having characteristic peaks at 2theta value of 4.9°±0.2°, 5.2°±0.2°, 9.9°±0.2°. The present invention provides a novel crystalline form of obeticholic acid, which has good stability, good processability and other favorable properties, and is suitable for storage and usage as a final product. In addition, the preparation method is simple, low cost, and has great value for the future optimization and development of obeticholic acid.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: April 30, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Xiaoyu Zhang
  • METHOD, DEVICE, AND SYSTEM FOR OFFLOADING ALGORITHMS
    Publication number: 20190124054
    Abstract: The processing load on a host processor is substantially reduced by offloading the transport layer security protocol, such as the TLS/SSL protocol, the transport layer protocol stack, such as the TCP/IP protocol stack, and the network control required to access a network, such as the Internet, onto an expansion device.
    Type: Application
    Filed: October 23, 2018
    Publication date: April 25, 2019
    Inventors: Xiaoyu ZHANG, Xiaowei JIANG
  • CRYSTALLINE FORM E OF TAFAMIDIS MEGLUMINE, PROCESS FOR PREPARATION AND USE THEREOF
    Publication number: 20190119226
    Abstract: The present disclosure relates to a novel crystalline form E of Tafamidis meglumine, process for preparation and use thereof. When compared with prior crystalline forms, the novel crystalline form of the present disclosure has the advantages of simple process and low hygroscopicity, which provides a new and better choice for the development of Tafamidis meglumine drug product and is of great significance.
    Type: Application
    Filed: May 5, 2017
    Publication date: April 25, 2019
    Inventors: Minhua Chen, Yanfeng Zhang, Jiaoyang Li, Xiaoyu Zhang
  • METHOD, DEVICE, AND SYSTEM FOR TASK PROCESSING
    Publication number: 20190123902
    Abstract: A number of RSA computing tasks that have different word lengths which are less than a maximum word length of an operand register are processed at the same time by combining a number of different word lengths to be equal to or less than the maximum word length of the operand register.
    Type: Application
    Filed: October 24, 2018
    Publication date: April 25, 2019
    Inventor: Xiaoyu ZHANG
  • Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4?-(trifluoromethoxy) [1,1?-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
    Patent number: 10266523
    Abstract: The present disclosure relates to novel crystalline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-methyl-4?-(trifluoromethoxy) [1,1?-biphenyl]-3-carboxamide monophosphate, and process of preparation thereof. The crystalline form of the monophosphate of a compound of formula (I) has low hygroscopicity, is convenient to store, has better stability than that of diphosphonate in prior art, can avoid the risk of crystal transformation in the development and production of the drug. The preparation method is simple, has low cost, and has important value for further optimization and development of the drug.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: April 23, 2019
    Assignee: CRYSTAL PHARMATECH CO., LTD.
    Inventors: Minhua Chen, Yanfeng Zhang, Fei Lu, Xiaoyu Zhang
  • MULTI-CHANNEL REAL-TIME PHASE MODULATION FOR EMI REDUCTION IN AN ULTRASOUND DEVICE
    Publication number: 20190099624
    Abstract: Methods for reducing electromagnetic interference arising from use of multiple ultrasound transducers in an array, particularly inside a human body that is inside a magnetic resonance imaging device. Electrical signals driving the transducers are offset in phase with respect to one another so as to achieve maximum offset of electrical and magnetic fields arising from such signals and transducers. Phase offsets are dynamically adjusted to respond to changes in driving amplitudes and frequencies so as to maintain optimal reduction of electromagnetic interference.
    Type: Application
    Filed: October 3, 2017
    Publication date: April 4, 2019
    Inventors: Ron Kurtz, Patrick Leonard, Xiaoyu Zhang
  • HYDROCHLORIDE SALT CRYSTAL OF DRUG FOR TREATING OR PREVENTING JAK-ASSOCIATED DISEASE AND PREPARATION METHOD THEREOF
    Publication number: 20190100519
    Abstract: The present disclosure disclosed crystalline forms of Filgotinib hydrochloride for treating or preventing JAK-associated diseases, and preparation methods, pharmaceutical compositions, and formulations thereof. The present disclosure also disclosed the use of crystalline forms of Filgotinib hydrochloride in the prevention and/or treatment of diseases associated with JAK family. In comparison to the known crystalline forms, the crystalline forms of the present disclosure show more favorable properties in terms of formulation engineering, such as higher stability under low water activity conditions, simplicity in the preparation process and/or higher solubility.
    Type: Application
    Filed: March 21, 2017
    Publication date: April 4, 2019
    Applicant: CRYSTAL PHARMATECH CO., LTD.
    Inventors: Minhua CHEN, Yanfeng ZHANG, Kai LIU, Xiaoyu ZHANG
  • Crystal form of neratinib maleate and preparation method therefor
    Patent number: 10246437
    Abstract: The present invention relates to novel crystalline forms of Neratinib maleate and the preparation method thereof. The novel crystalline forms of Neratinib maleate in the present invention have high solubility, good stability, good processability, easy post-treatment process and other favorable properties. The preparation method is simple, low cost, and has an important value for future optimization and development of the drug.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: April 2, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Xiaoyu Zhang
  • Crystal form of lenvatinib methanesulfonate salt and preparation method thereof
    Patent number: 10246418
    Abstract: The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer. The novel crystalline form of mesylate of the present disclosure has good solubility, stability, and remarkable purification effect in process. The preparation method of this novel crystalline form is simple, low cost, and has an important value for future optimization and development of the drug.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: April 2, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Xiaoyu Zhang
  • CRYSTALLINE FORM A OF 2-[(2R)-2-METHYL-2-PYRROLIDYL]-1H-BENZIMIDAZOLE-7-CARBOXAMIDE DIHYDROCHLORIDE AND PREPARATION METHOD THEREOF
    Publication number: 20190092756
    Abstract: Provided are a crystalline form A of 2-[(2R)-2-methyl-2-pyrrolidyl]-1H-benzimidazole-7-carboxamide dihydrochloride and the preparation method and use thereof. The X-ray powder diffraction pattern of crystalline form A shows characteristic peaks at 2theta values of 8.3°±0.2°, 26.7°±0.2°, 16.1°±0.2°. Crystalline form A, compared with the existing crystalline forms, has a surprisingly excellent solubility, mechanical and storage stabilities and particle size distribution, is a more ideal crystalline fotbnn compared with the prior art forms, better satisfies medicinal requirements, and plays an important role in future optimization and development of the drug.
    Type: Application
    Filed: March 8, 2017
    Publication date: March 28, 2019
    Inventors: Minhua Chen, Yanfeng Zhang, Kai Liu, Xiaoyu Zhang